170688-59-2Relevant academic research and scientific papers
BMS-201620: A selective beta 3 agonist
Washburn,Sun,Bisacchi,Wu,Cheng,Sher,Ryono,Gavai,Poss,Girotra,McCann,Mikkilineni,Dejneka,Wang,Merchant,Morella,Arbeeny,Harper,Slusarchyk,Skwish,Russell,Allen,Tesfamariam,Frohlich,Abboa-Offei,Cap,Waldron,George,Young,Dickinson,Seymour
, p. 3525 - 3529 (2007/10/03)
A series of N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides were prepared and evaluated for their human β3 adrenergic receptor agonist activity. SAR studies led to the identification of BMS-201620 (39), a potent β3 full agonist (Ki=93nM, 93% activation). Based on its favorable safety profile, BMS-201620 was chosen for clinical evaluation.
